Our core technology was developed by the companies within the consortium spearheaded by Richard Cornell. It is an advanced formulation of bioactive glasses, which has been designed from the start to optimise its various functions - unlike our competitors.
​
The two key functions are: A) to stimulate new bone tissue, and B) to fight infection by being bactericidal to key pathogens without the use of antibiotics.
​
Our products are categorised as medical devices and not pharmaceuticals.
Our Core Technology
Key Products
Granules
Our complex formulation of bioactive glasses has been designed and optimised to: A) Stimulate new bone formation, while B) being powerfully bactericidal (over 3-log10 over 7 days) against key gram-positive and gram-negative bacteria.
​
Of the many uses of this product, there is a large market in the treatment of open fractures.
Injectable
Our design process has carefully selected and optimised the carrier to ensure both the promotion of bone healing, and the bactericidal properties are not adversely affected.
There are many indications for clinical use of this product. A large market is spinal surgery.
We have taken full advantage of the design freedoms offered by our advanced bioactive glass formulations. In our controlled-release products we pace each of the functions to suit treatment requirements.
​
These exciting products can be used in a wide range of treatments. Its use in revision surgery of infected total joint replacement has a particularly large market.
Controlled Release